A population-based analysis to determine the impact of the 13-valent pneumococcal conjugate vaccine on community-acquired pneumonia in British Columbia, Canada

Abstract

BackgroundPneumonia is a leading cause of morbidity and mortality globally. We determined the impact of 13-valent pneumococcal conjugate vaccine (PCV13) use on community-acquired pneumonia (CAP) rates eight years after the vaccine was introduced in the infant immunization program. MethodsUsing diagnostic codes from administrative databases, we calculated the overall and age-specific CAP incidence per month (2000–2018). Changes in the CAP incidence before and after the PCV13 vaccine program introduction were evaluated using negative binomial regression model adjusting for 7-valent pneumococcal conjugate vaccine program. ResultsThe PCV13 vaccine infant immunization program was associated with declining CAP incidence among children aged 0–2 years (adjusted Incidence Rate Ratio (aIRR): 0.91; 95% CI: 0.87–0.96). Overall CAP incidence did not decrease in those aged 3–5 years (0.98; 95% CI: 0.93–1.04), 6–17 years (1.02; 95% CI: 0.97–1.08), 18–49 years (1.02; 95% CI:0.98–1.05), 50–64 years (1.07; 95% CI: 1.04–1.11), ≥65 years (1.05; 95% CI:1.02–1.08). ConclusionsThe PCV13 infant immunization program is temporally associated with a reduction in CAP incidence in vaccine target age group. However, no significant decrease in CAP incidence in other age groups warrants further study of the etiology of CAP to develop and implement effective prevention programs.